Autologous cell therapy market is predicted to reach USD 30.12 billion at a CAGR of 19.56% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Autologous cell therapy market”.

The autologous cell therapy market is estimated to register a CAGR of 19.56% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global autologous cell therapy market— Bristol Myers Squibb (US), Bayer AG (Germany), Autolus Therapeutics (UK), Sangamo Therapeutics (US), Holostem Terapie, Avanzate S.r.l. (Italy), Vericel Corporation (US), Opexa Therapeutics (US), BrainStorm Cell Therapeutics (US), Pharmicell Co., Inc. (South Korea), and Daiichi Sankyo Co., Ltd (Japan).

Market Highlights

The global autologous cell therapy market is accounted to register a CAGR of 19.56% during the forecast period and is estimated to reach USD 30.12 billion by 2032.

Autologous cell therapy (ACT) is a novel therapeutic intervention in which an individual's cells are cultured and expanded outside of the body before being reintroduced into the donor. The benefits of this approach include reduced risks from systemic immunological reactions, bio-incompatibility, and disease transmission associated with grafts or cells not cultivated from the individual.

The market has been driven by several factors, such as increasing awareness about personalized medical treatments and advancements in regenerative medicine. However, delayed regulatory approvals restrain the market's growth. Nonetheless, increased public and private sector investment creates more lucrative growth opportunities for market development.

Access full report @ https://www.marketresearchfuture.com/reports/autologous-cell-therapy-market-8959

Segment Analysis

The global autologous cell therapy market has been segmented based on therapy, application, source, and end user.

On the basis of therapy, the market is segmented into autologous stem cell therapy and autologous cellular immunotherapies. The Autologous Stem Cell Therapy segment held the majority share in 2022 due to the rising interest in personalized medical treatments. This novel approach uses a patient's own stem cells to treat a variety of medical conditions, making it an exciting aspect of regenerative medicine.

Based on application, the global autologous cell therapy market has been segmented into bone marrow, epidermis, and others. The bone marrow segment held the largest market share in 2022. This treatment strategy has gained momentum due to its potential to provide highly personalized and effective solutions for various forms of cancer.

Based on source, the global autologous cell therapy market has been segmented into cancer, cardiology, urology, neurovascular, gastrointestinal, general surgery, and pain management & trauma. The cancer segment held the largest market share in 2022. This therapy's primary driver is its effectiveness in treating a wide range of conditions related to bone marrow dysfunction, such as blood disorders, leukemia, and certain types of cancer.

On the basis of the end user, the market is segmented into hospitals & clinics and ambulatory centers. The hospitals & clinics segment held the largest market share during the forecast period owing to favorable reimbursement regulations and is preferred by patients for the treatment process.

Regional Analysis

The global autologous cell therapy market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Autologous cell therapy market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The autologous cell therapy market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Autologous cell therapy market comprises of Middle East, Africa, and Latin America.

Factors such as superior infrastructure and high per capita income are expected to increase the demand for autologous cell therapy in North America.

Moreover, factors such as the high number of market competitors in the area, as well as supportive government policies, possibly leading to the growth of the autologous cell therapy industry across the European region.

Additionally, the growing incidence of cancer and rising geriatric population are the major factors driving market growth in the Asia-Pacific region.

Furthermore, the rest of the world included the Middle East, Africa, and Latin America. The region accounted for the lowest market share in the autologous cell therapy market. This is due to the presence of poorer economies that lack effective healthcare infrastructure, and lower healthcare spending.

Key Findings of the Study

• The global Autologous cell therapy market is expected to reach USD 10.02 billion by 2030, at a CAGR of 30.12% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market, owing to the growing incidence of cancer and rising geriatric population.


• Based on application, the bone marrow segment was attributed to holding the largest market in 2022.


• Bristol Myers Squibb (US), Bayer AG (Germany), Autolus Therapeutics (UK), Pharmicell Co., Inc. (South Korea), and Daiichi Sankyo Co., Ltd (Japan) are the key market players.